{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:02:38Z","timestamp":1791435758965,"version":"4.3.3"},"reference-count":48,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007281","name":"National Drug and Alcohol Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1135991"],"award-info":[{"award-number":["1135991"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1190977"],"award-info":[{"award-number":["1190977"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Review"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Many countries have implemented strategies to reduce opioid\u2010related harms, including policies and prescribing restrictions. This study aimed to explore the lived experiences of Australians prescribed opioids for chronic non\u2010cancer pain (CNCP) in the context of increasing restrictions for accessing opioids.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Semi\u2010structured interviews were conducted with 14 Australians (aged 24\u201365\u2010years; 10 female\/4 male) self\u2010reporting regular use of prescribed opioids for CNCP. Participants were asked to describe their experiences using prescribed opioids, and perceived and actual changes in pain management including access to treatments. Using thematic analysis, four dominant themes were identified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In \u2018On them for a reason\u2019: <jats:italic>Opioids as a last resort<\/jats:italic>, participants described the role of opioids as an important tool for pain management following unsuccessful treatment using other strategies. In \u2018You're problematic\u2019: <jats:italic>Deepening stigma<\/jats:italic>, participants described how increased attention and restrictions led to increasing stigma of opioid use and CNCP. In \u2018We didn't cause the opioid epidemic\u2019: <jats:italic>Perceiving and redirecting blame<\/jats:italic>, participants described feeling unfairly blamed for public health problems and an \u2018opioid epidemic\u2019 they described as \u2018imported\u2019 from America, drawing distinctions between legitimate and illegitimate opioid use. Finally, in \u2018Where do we go from here?\u2019: <jats:italic>Fearing the future<\/jats:italic>, participants described anticipating further restrictions and associating these with increased pain and disability.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion and Conclusions<\/jats:title><jats:p>The experience of being prescribed opioids for CNCP in Australia in the context of increasing restrictions was characterised by stigma, blame and fear. There is a need to ensure people prescribed opioids for pain are considered when designing measures to reduce opioid\u2010related harms.<\/jats:p><\/jats:sec>","DOI":"10.1111\/dar.13879","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T05:50:00Z","timestamp":1716875400000},"page":"1625-1635","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["\u2018We didn't cause the opioid epidemic\u2019: The experiences of Australians prescribed opioids for chronic non\u2010cancer pain at a time of increasing restrictions"],"prefix":"10.1111","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9822-7083","authenticated-orcid":false,"given":"Ria E.","family":"Hopkins","sequence":"first","affiliation":[{"name":"National Drug and Alcohol Research Centre UNSW Sydney  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0851-0748","authenticated-orcid":false,"given":"Gabrielle","family":"Campbell","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre UNSW Sydney  Sydney Australia"},{"name":"School of Psychology University of Queensland  Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8513-2218","authenticated-orcid":false,"given":"Louisa","family":"Degenhardt","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre UNSW Sydney  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0452-8470","authenticated-orcid":false,"given":"Natasa","family":"Gisev","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre UNSW Sydney  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2007.131714"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.0163"},{"key":"e_1_2_9_4_1","volume-title":"Drug overdose deaths in the United States, 1999\u20132020. NCHS data brief no. 428","author":"Hedegaard H","year":"2021"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.01.010"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.07.018"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40429-018-0227-6"},{"key":"e_1_2_9_8_1","volume-title":"Opioid harm in Australia and comparisons between Australia and Canada","author":"Australian Institute of Health and Welfare","year":"2018"},{"key":"e_1_2_9_9_1","volume-title":"Trends in overdose and other drug\u2010induced deaths in Australia, 1997\u20132020","author":"Chrzanowska A","year":"2022"},{"key":"e_1_2_9_10_1","volume-title":"Final decisions and reasons for decisions by delegates of the secretary to the Department of Health Canberra","author":"Therapeutic Goods Administration","year":"2017"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja15.00929"},{"key":"e_1_2_9_12_1","unstructured":"HendrieD.Government to warn almost 5000 GPs over high rates of opioid prescribing. newsGP.2018."},{"key":"e_1_2_9_13_1","unstructured":"Pharmaceutical Benefits Scheme.Revised opioids PBS listings for the management of severe disabling pain. Canberra ACT; 2020. Available from:https:\/\/www.pbs.gov.au\/news\/2020\/05\/opioids-factsheet-files\/opioids-factsheet-2020-v3.pdf"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001939"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(00)00355-9"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.j.pain.0000460303.63948.8e"},{"key":"e_1_2_9_17_1","volume-title":"The cost of chronic pain in Australia","author":"Deloitte Access Economics","year":"2019"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.1496"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2003.03038.x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/314184"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-015083"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108664"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.01.015"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.11013"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002298"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-019-05301-2"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002420"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.13683"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103708"},{"key":"e_1_2_9_30_1","volume-title":"Impact of opioid regulatory reforms on people living with chronic pain","author":"4.2","year":"2022"},{"key":"e_1_2_9_31_1","volume-title":"National Pain Survey 2021. Baulkham Hills","author":"Chronic Pain Australia","year":"2021"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzm042"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-022-08946-8"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1207\/s15327019eb0904_5"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.soc.27.1.363"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2008.06.002"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnw078"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-020-3055-5"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmn.2009.03.007"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.103077"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000512"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.10.005"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/24740527.2021.1881886"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.2307\/2675505"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1525\/si.2004.27.1.23"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(89)90097-3"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40429-015-0074-7"},{"key":"e_1_2_9_49_1","volume-title":"Prescription opioids: information for health professionals Canberra","author":"Therapeutic Goods Administration","year":"2021"}],"container-title":["Drug and Alcohol Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dar.13879","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T15:40:36Z","timestamp":1726242036000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dar.13879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1111\/dar.13879"],"URL":"https:\/\/doi.org\/10.1111\/dar.13879","archive":["Portico"],"relation":{},"ISSN":["0959-5236","1465-3362"],"issn-type":[{"value":"0959-5236","type":"print"},{"value":"1465-3362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,27]]},"assertion":[{"value":"2023-08-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}